# Tenet Healthcare Corp: Form 10-Q for the period ended Mar 31, 2022

- Company: [Tenet Healthcare Corp](/companies/thc.md) (CIK 70318)
- Form: 10-Q
- Filed: 2022-04-29
- Accepted by EDGAR: Apr 29, 2022, 16:09 ET
- Period: 2022-03-31
- Accession: 0000070318-22-000029
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/70318/000007031822000029/thc-20220331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/70318/000007031822000029/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-01-01 to 2022-03-31 | $4.75bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Operating income | 3 months, 2022-01-01 to 2022-03-31 | $648.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2022-01-01 to 2022-03-31 | $227.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2022-01-01 to 2022-03-31 | $99.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-01-01 to 2022-03-31 | $280.0m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2022-01-01 to 2022-03-31 | $1.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-01-01 to 2022-03-31 | $1.30 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-01-01 to 2022-03-31 | 112,020,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2022-01-01 to 2022-03-31 | $228.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2022-01-01 to 2022-03-31 | $155.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-03-31 | $1.41bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-03-31 | $6.13bn | us-gaap:AssetsCurrent |
| Total assets | at 2022-03-31 | $26.65bn | us-gaap:Assets |
| Current liabilities | at 2022-03-31 | $4.67bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-03-31 | $22.24bn | us-gaap:Liabilities |
| Shareholders' equity | at 2022-03-31 | $1.06bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 123,686 characters.

### INTRODUCTION TO MANAGEMENT’S DISCUSSION AND ANALYSIS

The purpose of this section, Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), is to provide a narrative explanation of our financial statements that enables investors to better understand our business, to enhance our overall financial disclosures, to provide the context within which our financial information may be analyzed, and to provide information about the quality of, and potential variability of, our financial condition, results of operations and cash flows. MD&A, which should be read in conjunction with the accompanying Condensed Consolidated Financial Statements, includes the following sections:

- Management Overview
- Forward-Looking Statements
- Sources of Revenue for Our Hospital Operations Segment
- Results of Operations
- Liquidity and Capital Resources
- Critical Accounting Estimates

Our business consists of our Hospital Operations and other (“Hospital Operations”) segment, our Ambulatory Care segment and our Conifer segment. Our Hospital Operations segment is comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro‑hospitals and physician practices. At March 31, 2022, our subsidiaries operated 60 hospitals serving primarily urban and suburban communities in nine states. In April 2022, we completed the sale of a Hospital Operations segment micro‑hospital, which was classified as held for sale in the accompanying Condensed Consolidated Balance Sheet at March 31, 2022. In April 2021, we completed the sale of the majority of the urgent care centers then held by our Hospital Operations segment to an unaffiliated urgent care provider. In addition, in August 2021, we completed the sale of five Miami‑area hospitals and certain related operations (the “Miami Hospitals”) held by our Hospital Operations segment.

Our Ambulatory Care segment is comprised of the operations of USPI Holding Company, Inc. (“USPI”), in which we held an ownership interest of approximately 95% at March 31, 2022. USPI had interests in 404 ambulatory surgery centers (each, an “ASC”) (253 consolidated) and 24 surgical hospitals (eight consolidated) in 34 states at March 31, 2022. In April 2021, we completed the sale of 40 urgent care centers then held by our Ambulatory Care segment to an unaffiliated urgent care provider and transferred 24 imaging centers from our Ambulatory Care segment to our Hospital Operations segment.

Our Conifer segment provides revenue cycle management and value‑based care services to hospitals, health systems, physician practices, employers and other clients through our Conifer Holdings, Inc. subsidiary (“Conifer”). At March 31, 2022, Conifer provided services to over 660 Tenet and non‑Tenet hospitals and other clients nationwide. Nearly all of the services comprising the operations of our Conifer segment are provided by Conifer Health Solutions, LLC, in which we held an ownership interest of approximately 76% at March 31, 2022, or by one of its direct or indirect wholly owned subsidiaries.

Unless otherwise indicated, all financial and statistical information included in MD&A relates to our continuing operations, with dollar amounts expressed in millions (except per‑adjusted‑patient‑admission and per‑adjusted‑patient‑day amounts). Continuing operations information includes the results of our same 60 hospitals operated throughout the three months ended March 31, 2022 and 2021, as well as the Miami Hospitals sold in August 2021. Continuing operations information excludes the results of our hospitals and other businesses that have been classified as discontinued operations for accounting purposes. We believe this information is useful to investors because it includes the operations of all facilities in continuing operations for the period of time that we owned and operated them, and it reflects the recent trends we are experiencing with respect to volumes, revenues and expenses. We present certain metrics as a percentage of net operating revenues because a significant portion of our operating expenses are variable. In addition, we present certain metrics on a per‑adjusted-patient‑admission and per‑adjusted‑patient‑day basis to show trends other than volume.

In certain cases, information presented in MD&A for our Hospital Operations segment is described as presented on a same‑hospital basis, which includes the results of our same 60 hospitals operated throughout the three months ended March 31, 2022 and 2021, and excludes the results of the Miami Hospitals we sold in August 2021 and the results of our discontinued operations. We present same‑hospital data because we believe it provides investors with useful information regarding the performance of our current portfolio of hospitals and other operations that are comparable for the periods presented, as well as reflects recent trends we are experiencing with respect to volumes, revenues and expenses.

### MANAGEMENT OVERVIEW

### IMPACT OF THE COVID-19 PANDEMIC

The COVID‑19 pandemic generally and, most recently, the spread of the Omicron variant continued to impact all three segments of our business, as well as our patients, communities and employees, in the three months ended March 31, 2022. Broad economic factors resulting from the pandemic affected our patient volumes, service mix and revenue mix. In addition, the pandemic continued to have an adverse impact on certain of our operating expenses in the first quarter of 2022.

Various federal legislative actions, including additional funding for the Public Health and Social Services Emergency Fund (“PRF”), have mitigated some of the economic disruption caused by the COVID‑19 pandemic on our business. In the three months ended March 31, 2022 and 2021, we received cash payments of $5 million and $59 million, respectively, from the PRF and state and local grant programs. We recognized $6 million and $31 million, respectively, from these funds as grant income during the three-month periods in 2022 and 2021, respectively. In addition, we recognized $6 million in equity in earnings of unconsolidated affiliates in the accompanying Condensed Consolidated Statement of Operations during the three months ended March 31, 2021.

Throughout MD&A, we have provided additional information on the impact of the COVID‑19 pandemic on our results of operations and the steps we have taken, and are continuing to take, in response. The ultimate extent and scope of the pandemic and its future impact on our business remain unknown. For information about risks and uncertainties related to COVID‑19 that could affect our results of operations, financial condition and cash flows, see the Risk Factors section in this report and in Part I of our Annual Report on Form 10-K for the year ended December 31, 2021 (“Annual Report”).

### TRENDS AND STRATEGIES

As described above and throughout MD&A, we continue to experience negative impacts of the pandemic on our business in varying degrees. Most recently, primarily in January and February 2022, we were affected by a significant acceleration in COVID-19 cases associated with the Omicron variant. Throughout the COVID‑19 pandemic, we have taken, and we continue to take, various actions to increase our liquidity and mitigate the impact of reductions in our patient volumes and changes in our service mix and revenue mix. We have issued new senior unsecured notes and senior secured first lien notes, redeemed existing senior unsecured notes and senior secured first lien notes, including those with the highest interest rates of all of our long‑term debt, and amended our senior secured revolving credit facility (as amended to date, the “Credit Agreement”). We also decreased our employee headcount throughout the organization at the outset of the COVID-19 pandemic, and we deferred certain operating expenses that were not expected to impact our response to the pandemic. In addition, we reduced certain variable costs across the enterprise. Together with government relief packages, we believe these actions supported our ability to provide essential patient services during the initial uncertainty caused by the COVID-19 pandemic and continue to do so. For further information on our liquidity, see “Liquidity and Capital Resources” below.

We have experienced, and continue to experience, increased competition with other healthcare providers in recruiting and retaining qualified personnel responsible for the operation of our facilities. There is a limited availability of experienced medical support personnel nationwide, which drives up the wages and benefits required to recruit and retain employees. In particular, like others in the healthcare industry, we continue to experience a shortage of critical‑care nurses in certain disciplines and geographic areas. This shortage has been exacerbated by the COVID‑19 pandemic as more nurses choose to retire early, leave the workforce or take travel assignments. In some areas, the increased demand for care of COVID‑19 patients in our hospitals, as well as the direct impact of COVID‑19 on physicians, employees and their families, have put a strain on our resources and staff. Over the past two years, we have had to rely on higher-cost temporary contract labor, which we compete with other healthcare providers to secure, and pay premiums above standard compensation for essential workers. In addition, we have experienced significant price increases in medical supplies, particularly for personal protective equipment (“PPE”), and we have encountered supply‑chain disruptions, including shortages and delays.

We believe that several key trends are also continuing to shape the demand for healthcare services: (1) consumers, employers and insurers are actively seeking lower‑cost solutions and better value as they focus more on healthcare spending; (2) patient volumes are shifting from inpatient to outpatient settings due to technological advancements and demand for care that is more convenient, affordable and accessible; (3) the growing aging population requires greater chronic disease management and higher‑acuity treatment; and (4) consolidation continues across the entire healthcare sector. In addition, the healthcare industry, in general, and the acute care hospital business, in particular, have experienced significant regulatory uncertainty based, in large part, on administrative, legislative and judicial efforts to limit, alter or repeal the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (“Affordable Care Act”). It is difficult to predict the full impact of regulatory uncertainty on our future revenues and operations.

*Expansion of Our Ambulatory Care Segment—*In response to these trends, we continue to focus on opportunities to expand our Ambulatory Care segment through acquisitions, organic growth, construction of new outpatient centers and strategic partnerships. During the years ended December 31, 2021 and 2020, we invested $1.315 billion and $1.200 billion, respectively, to acquire ownership interests in new ASCs, increase our ownership interests in existing facilities and invest in de novo facilities. This activity included the acquisition of ownership interests in 86 ASCs and related ambulatory support services (collectively, the “SCD Centers”) from Surgical Center Development #3, LLC and Surgical Center Development #4, LLC (“SCD”) in December 2021. USPI and SCD’s principals have also entered into a joint venture and development agreement under which USPI will have the exclusive option to partner with affiliates of SCD on the future development of a minimum target of 50 de novo ASCs over a period of five years.

During the three months ended March 31, 2022, we acquired controlling interests in two ASCs in Florida and one in New Hampshire, and we acquired a noncontrolling interest in an ASC located in New Jersey. During the same period, we also acquired controlling ownership interests in three previously unconsolidated SCD Centers located in Florida, Pennsylvania and Texas. In addition, we opened two new ASCs in the first quarter of 2022 – one in Florida and one in North Carolina. We believe USPI’s ASCs and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in medical technology and due to the lower cost structure and greater efficiencies that are attainable at a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to increase. Historically, our outpatient services have generated significantly higher margins for us than inpatient services.

*Driving Growth in Our Hospital Systems—*We remain committed to better positioning our hospital systems and competing more effectively in the ever‑evolving healthcare environment by focusing on driving performance through operational effectiveness, increasing capital efficiency and margins, investing in our physician enterprise, particularly our specialist network, enhancing patient and physician satisfaction, growing our higher‑demand and higher‑acuity clinical service lines (including outpatient lines), expanding patient and physician access, and optimizing our portfolio of assets. Over the past several years, we have undertaken enterprise‑wide cost‑efficiency measures, and we continue to transition certain support operations offshore to our Global Business Center (“GBC”) in the Philippines. We incurred restructuring charges in conjunction with these initiatives in the three months ended March 31, 2022, and we could incur additional such charges in the future.

We also continue to exit service lines, businesses and markets that we believe are no longer a core part of our long‑term growth strategy. In April 2021, we divested the majority of our urgent care centers operated under the MedPost and CareSpot brands by our Hospital Operations and Ambulatory Care segments. In addition, we completed the sale of the Miami Hospitals in August 2021. We intend to further refine our portfolio of hospitals and other healthcare facilities when we believe such refinements will help us improve profitability, allocate capital more effectively in areas where we have a stronger presence, deploy proceeds on higher‑return investments across our business, enhance cash flow generation, reduce our debt and lower our ratio of debt‑to‑Adjusted EBITDA.

*Improving the Customer Care Experience—*As consumers continue to become more engaged in managing their health, we recognize that understanding what matters most to them and earning their loyalty is imperative to our success. As such, we have enhanced our focus on treating our patients as traditional customers by: (1) establishing networks of physicians and facilities that provide convenient access to services across the care continuum; (2) expanding service lines aligned with growing community demand, including a focus on aging and chronic disease patients; (3) offering greater affordability and predictability, including simplified registration and discharge procedures, particularly in our outpatient centers; (4) improving our culture of service; and (5) creating health and benefit programs, patient education and health literacy materials that are customized to the needs of the communities we serve. Through these efforts, we intend to improve the customer care experience in every part of our operations.

*Driving Conifer’s Growth—*Conifer serves over 660 Tenet and non‑Tenet hospitals and other clients nationwide. In addition to providing revenue cycle management services to health systems and physicians, Conifer provides support to both providers and self‑insured employers seeking assistance with clinical integration, financial risk management and population health management. Conifer remains focused on driving growth by continuing to market and expand its revenue cycle management and value‑based care solutions businesses. We believe that our success in growing Conifer and increasing its profitability depends in part on our success in executing the following strategies: (1) attracting hospitals and other healthcare providers that currently handle their revenue cycle management processes internally as new clients; (2) generating new client relationships through opportunities from USPI and Tenet’s acute care hospital acquisition and divestiture activities; (3) expanding revenue cycle management and value‑based care service offerings through organic development and small acquisitions; and (4) leveraging data from tens of millions of patient interactions for continued enhancement of the value‑based care environment to drive competitive differentiation.

*Improving Profitability—*As we return to more normal operations, we continue to focus on growing patient volumes and effective cost management as a means to improve profitability. We believe our inpatient admissions have been constrained in recent years (prior to the COVID‑19 pandemic) by increased competition, utilization pressure by managed care organizations, new delivery models that are designed to lower the utilization of acute care hospital services, the effects of higher patient co‑pays, co‑insurance amounts and deductibles, changing consumer behavior, and adverse economic conditions and demographic trends in certain of our markets. However, we also believe that emphasis on higher‑demand clinical service lines (including outpatient services), focus on expanding our ambulatory care business, cultivation of our culture of service, participation in Medicare Advantage health plans that have been experiencing higher growth rates than traditional Medicare, and contracting strategies that create shared value with payers should help us grow our patient volumes over time. We are also continuing to explore new opportunities to enhance efficiency, including further integration of enterprise‑wide centralized support functions, outsourcing additional functions unrelated to direct patient care, and reducing clinical and vendor contract variation.

*Reducing Our Leverage Over Time—*All of our outstanding long‑term debt has a fixed rate of interest, except for outstanding borrowings, if any, under our Credit Agreement, and the maturity dates of our notes are staggered from 2023 through 2031. We believe that our capital structure minimizes the near‑term impact of increased interest rates, and the staggered maturities of our debt allow us to refinance our debt over time. During the three months ended March 31, 2022, we redeemed all $700 million aggregate principal amount outstanding of our 7.500% senior secured first lien notes due 2025 (the “2025 Senior Secured First Lien Notes”) in advance of their maturity date using cash on hand. In addition, we repurchased $103 million aggregate principal amount outstanding of our 6.750% senior unsecured notes due 2023 (the “2023 Senior Unsecured Notes”) through a series of open‑market transactions in March 2022 using cash on hand. We anticipate these redemption and repurchase transactions will reduce future annual cash interest expense payments by approximately $60 million. It remains our long‑term objective to reduce our debt and lower our ratio of debt‑to‑Adjusted EBITDA, primarily through more efficient capital allocation and Adjusted EBITDA growth, which should lower our refinancing risk.

Our ability to execute on our strategies and respond to the aforementioned trends is subject to the extent and scope of the impact on our operations of the COVID‑19 pandemic, as well as a number of other risks and uncertainties, all of which may cause actual results to be materially different from expectations. For information about risks and uncertainties that could affect our results of operations, see the Forward‑Looking Statements and Risk Factors sections in this report, as well as the Forward‑Looking Statements and Risk Factors sections in Part I of our Annual Report.

### RESULTS OF OPERATIONS—OVERVIEW

The following tables present selected operating statistics for our Hospital Operations and Ambulatory Care segments, as well as consolidated net operating revenues and expenses, in each case for the three months ended March 31, 2022 and 2021 on a continuing operations basis.

| Selected Operating Statistics Hospital Operations – hospitals and related outpatient facilities: | Continuing Operations Three Months Ended March 31, 2022 | 2021 | Increase (Decrease) |  |
| --- | ---: | ---: | ---: | ---: |
| Number of hospitals (at end of period) | 60 | 65 | (5) | (1) |
| Total admissions | 127,781 | 147,674 | (13.5)% |  |
| Adjusted patient admissions(2) | 227,933 | 251,017 | (9.2)% |  |
| Paying admissions (excludes charity and uninsured) | 121,802 | 138,756 | (12.2)% |  |
| Charity and uninsured admissions | 5,979 | 8,918 | (33.0)% |  |
| Admissions through emergency department | 97,688 | 112,730 | (13.3)% |  |
| Emergency department visits, outpatient | 500,659 | 450,830 | 11.1% |  |
| Total emergency department visits | 598,347 | 563,560 | 6.2% |  |
| Total surgeries | 84,166 | 89,964 | (6.4)% |  |
| Patient days — total | 705,627 | 797,489 | (11.5)% |  |
| Adjusted patient days(2) | 1,224,824 | 1,321,890 | (7.3)% |  |
| Average length of stay (days) | 5.52 | 5.40 | 2.2% |  |
| Average licensed beds | 15,395 | 17,178 | (10.4)% |  |
| Utilization of licensed beds(3) | 50.9% | 51.6% | (0.7)% | (1) |
| Total visits | 1,373,188 | 1,401,217 | (2.0)% |  |
| Paying visits (excludes charity and uninsured) | 1,295,352 | 1,312,096 | (1.3)% |  |
| Charity and uninsured visits | 77,836 | 89,121 | (12.7)% |  |
| **Ambulatory Care:** |  |  |  |  |
| Total consolidated facilities (at end of period) | 261 | 291 | (30) | (1) |
| Total consolidated cases | 300,320 | 553,814 | (45.8)% |  |

(1) The change is the difference between the 2022 and 2021 amounts shown.

(2) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

(3) Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

Total admissions decreased by 19,893, or 13.5%, and total surgeries decreased by 5,798, or 6.4%, in the three months ended March 31, 2022 compared to the three months ended March 31, 2021. Total emergency department visits increased 6.2% in the three months ended March 31, 2022 compared to the same period in 2021. The decrease in our patient volumes from continuing operations in the three months ended March 31, 2022 compared to the three months ended March 31, 2021 is primarily attributable to the sale of the Miami Hospitals in August 2021 and the impact of the Omicron variant in January and February 2022. The decrease in Ambulatory Care total consolidated cases of 45.8% in the three months ended March 31, 2022 compared to the same period in 2021 is primarily due to the divestiture of USPI’s urgent care centers and the realignment of its imaging centers under our Hospital Operations segment.

| Revenues Net operating revenues: | Continuing Operations Three Months Ended March 31, 2022 | 2021 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Hospital Operations prior to inter-segment eliminations | $3,798 | $3,947 | (3.8)% |
| Ambulatory Care | 738 | 646 | 14.2% |
| Conifer | 324 | 310 | 4.5% |
| Inter-segment eliminations | (115) | (122) | (5.7)% |
| **Total** | **$4,745** | **$4,781** | **(0.8)%** |

Net operating revenues decreased by $36 million, or 0.8%, in the three months ended March 31, 2022 compared to the same period in 2021, primarily due to the loss of revenues in our Hospital Operations segment from the Miami Hospitals we sold in August 2021 and lower patient volumes, partially offset by high patient acuity and negotiated commercial rate increases. On a consolidated basis, this decrease was further offset by higher revenues from our Ambulatory Care segment, which increased $92 million, or 14.2%, in the 2022 period compared to the 2021 period. This increase was largely driven by our recently acquired ASCs, higher surgical patient volumes and negotiated commercial rate increases. Conifer’s revenues, net of intercompany eliminations, increased $21 million, or 11.2%, during the three months ended March 31, 2022 compared to the same period in 2021, primarily due to contractual rate increases and new business expansion. During the three months ended March 31, 2022 and 2021, we recognized net grant income of $6 million and $31 million, respectively, which amounts are not included in net operating revenues.

Our accounts receivable days outstanding (“AR Days”) from continuing operations were 58.9 days at March 31, 2022 and 57.0 days at December 31, 2021, primarily due to the approval of Texas’ Medicaid supplemental funding programs by the Centers for Medicare and Medicaid Services (“CMS”) at the end of March 2022, which resulted in our recognition of $57 million of revenue in the three months ended March 31, 2022. This revenue has not yet been collected given that the programs were just recently approved. Our AR Days target is less than 55 days. AR Days are calculated as our accounts receivable from continuing operations on the last date in the quarter divided by our net operating revenues from continuing operations for the quarter ended on that date divided by the number of days in the quarter. This calculation includes our Hospital Operations segment’s contract assets. The AR Days calculation excludes (i) urgent care centers operated under the MedPost and CareSpot brands, which we divested in April 2021, (ii) the Miami Hospitals, which we sold in August 2021, and (iii) our California provider fee revenues.

| Selected Operating Expenses Hospital Operations: | Continuing Operations Three Months Ended March 31, 2022 | 2021 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Salaries, wages and benefits | $1,820 | $1,857 | (2.0)% |
| Supplies | 583 | 646 | (9.8)% |
| Other operating expenses | 774 | 916 | (15.5)% |
| **Total** | **$3,177** | **$3,419** | **(7.1)%** |
| **Ambulatory Care:** |  |  |  |
| Salaries, wages and benefits | $194 | $174 | 11.5% |
| Supplies | 201 | 157 | 28.0% |
| Other operating expenses | 105 | 103 | 1.9% |
| **Total** | **$500** | **$434** | **15.2%** |
| **Conifer:** |  |  |  |
| Salaries, wages and benefits | $168 | $170 | (1.2)% |
| Supplies | 1 | 1 | —% |
| Other operating expenses | 63 | 53 | 18.9% |
| **Total** | **$232** | **$224** | **3.6%** |
| **Total:** |  |  |  |
| Salaries, wages and benefits | $2,182 | $2,201 | (0.9)% |
| Supplies | 785 | 804 | (2.4)% |
| Other operating expenses | 942 | 1,072 | (12.1)% |
| **Total** | **$3,909** | **$4,077** | **(4.1)%** |
| **Rent/lease expense(1):** |  |  |  |
| Hospital Operations | $70 | $77 | (9.1)% |
| Ambulatory Care | 27 | 27 | —% |
| Conifer | 3 | 3 | —% |
| **Total** | **$100** | **$107** | **(6.5)%** |

(1) Included in other operating expenses.

| Selected Operating Expenses per Adjusted Patient Admission Hospital Operations: | Continuing Operations Three Months Ended March 31, 2022 | 2021 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Salaries, wages and benefits per adjusted patient admission(1) | $7,985 | $7,396 | 8.0% |
| Supplies per adjusted patient admission(1) | 2,557 | 2,571 | (0.5)% |
| Other operating expenses per adjusted patient admission(1) | 3,393 | 3,647 | (7.0)% |
| **Total per adjusted patient admission** | **$13,935** | **$13,614** | **2.4%** |

(1) Adjusted patient admissions represents actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

Salaries, wages and benefits expense for our Hospital Operations segment decreased $37 million, or 2.0%, in the three months ended March 31, 2022 compared to the same period in 2021. This change was primarily attributable to the sale of the Miami Hospitals in August 2021 and our continued focus on cost-efficiency measures, partially offset by increased contract labor costs, increased overtime expense and annual merit increases for certain of our employees. On a per‑adjusted‑patient‑admission basis, salaries, wages and benefits increased 8.0% in the three months ended March 31, 2022 compared to the three months ended March 31, 2021, primarily due to the expenses mentioned above.

Supplies expense for our Hospital Operations segment decreased $63 million, or 9.8%, during the three months ended March 31, 2022 compared to the three months ended March 31, 2021. This decrease was primarily attributable to the sale of the Miami Hospitals, the decrease in patient volumes during the 2022 period and our cost-efficiency measures, partially offset by increased costs for certain supplies as a result of the COVID-19 pandemic and high patient acuity. On a per‑adjusted‑patient‑admission basis, supplies expense decreased 0.5% in the three months ended March 31, 2022 compared to the three months ended March 31, 2021, primarily due to the cost-efficiency measures described above.

Other operating expenses for our Hospital Operations segment decreased $142 million, or 15.5%, in the three months ended March 31, 2022 compared to the same period in 2021. The decrease was primarily attributable to sale of the Miami Hospitals, a gain of $69 million realized from the sale of several medical office buildings in the three months ended March 31, 2022, and our continued focus on cost-efficiency measures. On a per‑adjusted‑patient‑admission basis, other operating expenses in the three months ended March 31, 2022 decreased 7.0% compared to the same period in 2021, primarily due to the items mentioned above.

### LIQUIDITY AND CAPITAL RESOURCES OVERVIEW

Cash and cash equivalents were $1.405 billion at March 31, 2022 compared to $2.364 billion at December 31, 2021.

Significant cash flow items in the three months ended March 31, 2022 included:

- Net cash provided by operating activities before interest, taxes, discontinued operations, and restructuring charges, acquisition‑related costs, and litigation costs and settlements of $458 million (including $5 million from federal grants);
- Proceeds from the sale of facilities and other assets of $148 million;
- Debt payments of $879 million, including the redemption of all $700 million aggregate principal amount outstanding of our 2025 Senior Secured First Lien Notes and the repurchase of $103 million aggregate principal amount outstanding of our 2023 Senior Unsecured Notes;
- Interest payments of $166 million;
- Capital expenditures of $155 million;
- $135 million of distributions paid to noncontrolling interests;
- Payments totaling $56 million for restructuring charges, acquisition‑related costs, and litigation costs and settlements; and
- $40 million of payments for purchases of businesses or joint venture interests.

Net cash provided by operating activities was $228 million in the three months ended March 31, 2022 compared to $534 million in the three months ended March 31, 2021. Key factors contributing to the change between the 2022 and 2021 periods include the following:

- $194 million of Medicare advances recouped in the three months ended March 31, 2022 compared to no amounts recouped during the same period in 2021;
- $5 million of cash received from grants in the three months ended March 31, 2022 compared to $31 million received in the three months ended March 31, 2021;
- Decreased cash receipts of $12 million related to supplemental Medicaid programs in California and Texas; and
- The timing of other working capital items.

### FORWARD-LOOKING STATEMENTS

This report includes “forward‑looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements, other than statements of historical or present facts, that address activities, events, outcomes, business strategies and other matters that we plan, expect, intend, assume, believe, budget, predict, forecast, project, target, estimate or anticipate (and other similar expressions) will, should or may occur in the future are forward‑looking statements, including (but not limited to) disclosure regarding (i) the impact of the COVID-19 pandemic, (ii) our future earnings, financial position, and operational and strategic initiatives, and (iii) developments in the healthcare industry. Forward‑looking statements represent management’s expectations, based on currently available information, as to the outcome and timing of future events, but, by their nature, address matters that are indeterminate. They involve known and unknown risks, uncertainties and other factors, many of which we are unable to predict or control, that may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward‑looking statements. Such factors include, but are not limited to, the risks described in the Forward‑Looking Statements and Risk Factors sections in Part I of our Annual Report and the Risk Factors section in Part II of this report.

When considering forward‑looking statements, you should keep in mind the risk factors and other cautionary statements in our Annual Report and in this report. Should one or more of the risks and uncertainties described in these reports occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward‑looking statement. We specifically disclaim any obligation to update any information contained in a forward‑looking statement or any forward‑looking statement in its entirety except as required by law.

All forward‑looking statements attributable to us are expressly qualified in their entirety by this cautionary information.

### SOURCES OF REVENUE FOR OUR HOSPITAL OPERATIONS SEGMENT

We earn revenues for patient services from a variety of sources, primarily managed care payers and the federal Medicare program, as well as state Medicaid programs, indemnity‑based health insurance companies and uninsured patients (that is, patients who do not have health insurance and are not covered by some other form of third‑party arrangement).

The following table presents the sources of net patient service revenues less implicit price concessions for our hospitals and related outpatient facilities, expressed as percentages of net patient service revenues less implicit price concessions from all sources:

| Net Patient Service Revenues Less Implicit Price Concessions from: 2022 | Three Months Ended March 31, 2021 |  | Increase (Decrease)(1) |
| --- | ---: | ---: | ---: |
| Medicare | 17.6% | 18.8% | (1.2)% |
| Medicaid | 5.5% | 7.1% | (1.6)% |
| Managed care(2) | 71.1% | 68.0% | 3.1% |
| Uninsured | 1.1% | 1.3% | (0.2)% |
| Indemnity and other | 4.7% | 4.8% | (0.1)% |

(1) The change is the difference between the 2022 and 2021 percentages presented.

(2) Includes Medicare and Medicaid managed care programs.

32

Our payer mix on an admissions basis for our hospitals and related outpatient facilities, expressed as a percentage of total admissions from all sources, is presented below:

| Admissions from: | Three Months Ended March 31, 2022 | 2021 | Increase (Decrease)(1) |
| --- | ---: | ---: | ---: |
| Medicare | 21.5% | 21.4% | 0.1% |
| Medicaid | 5.6% | 5.7% | (0.1)% |
| Managed care(2) | 64.8% | 63.7% | 1.1% |
| Charity and uninsured | 4.7% | 6.0% | (1.3)% |
| Indemnity and other | 3.4% | 3.2% | 0.2% |

(1) The change is the difference between the 2022 and 2021 percentages presented.

(2) Includes Medicare and Medicaid managed care programs.

### GOVERNMENT PROGRAMS

CMS is an agency of the U.S. Department of Health and Human Services (“HHS”) that administers a number of government programs authorized by federal law; it is the single largest payer of healthcare services in the United States. Medicare is a federally funded health insurance program primarily for individuals 65 years of age and older, as well as some younger people with certain disabilities and conditions, and is provided without regard to income or assets. Medicaid is co‑administered by the states and is jointly funded by the federal government and state governments. Medicaid is the nation’s main public health insurance program for people with low incomes and is the largest source of health coverage in the United States. The Children’s Health Insurance Program (“CHIP”), which is also co‑administered by the states and jointly funded, provides health coverage to children in families with incomes too high to qualify for Medicaid, but too low to afford private coverage. Unlike Medicaid, the CHIP is limited in duration and requires the enactment of reauthorizing legislation. Funding for the CHIP has been reauthorized through federal fiscal year 2027.

### Medicare

Medicare offers its beneficiaries different ways to obtain their medical benefits. One option, the Original Medicare Plan (which includes “Part A” and “Part B”), is a fee‑for‑service (“FFS”) payment system. The other option, called Medicare Advantage (sometimes called “Part C” or “MA Plans”), includes health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”), private FFS Medicare special needs plans and Medicare medical savings account plans. Our total net patient service revenues from continuing operations of the hospitals and related outpatient facilities in our Hospital Operations segment for services provided to patients enrolled in the Original Medicare Plan were $619 million and $688 million for the three months ended March 31, 2022 and 2021, respectively.

A general description of the types of payments we receive for services provided to patients enrolled in the Original Medicare Plan is provided in our Annual Report. Recent regulatory and legislative updates to the terms of these payment systems and their estimated effect on our revenues can be found under “Regulatory and Legislative Changes” below.

### Medicaid

Medicaid programs and the corresponding reimbursement methodologies vary from state‑to‑state and from year‑to‑year. Even prior to the COVID‑19 pandemic, several states in which we operate faced budgetary challenges that resulted in reduced Medicaid funding levels to hospitals and other providers. Because most states must operate with balanced budgets, and the Medicaid program is generally a significant portion of a state’s budget, states can be expected to adopt or consider adopting future legislation designed to reduce or not increase their Medicaid expenditures. In addition, some states delay issuing Medicaid payments to providers to manage state expenditures. As an alternative means of funding provider payments, many of the states in which we operate have adopted supplemental payment programs authorized under the Social Security Act. Continuing pressure on state budgets and other factors, including legislative and regulatory changes, could result in future reductions to Medicaid payments, payment delays or changes to Medicaid supplemental payment programs. Federal government denials or delayed approvals of waiver applications or extension requests by the states in which we operate could materially impact our Medicaid funding levels.

Estimated revenues under various state Medicaid programs, including state‑funded Medicaid managed care programs, constituted approximately 18.8% and 16.9% of total net patient service revenues less implicit price concessions of our acute care hospitals and related outpatient facilities for the three months ended March 31, 2022 and 2021, respectively. We also receive disproportionate share hospital (“DSH”) and other supplemental revenues under various state Medicaid programs. For the three months ended March 31, 2022 and 2021, our total Medicaid revenues attributable to DSH and other supplemental revenues were approximately $119 million and $180 million, respectively. The decrease between the two three‑month periods was primarily attributable to $57 million of assessments we recognized related to the Texas Comprehensive Hospital Increase Reimbursement Program (“CHIRP”) following its approval in 2022. During the three months ended March 31, 2022, we also recognized $114 million of revenue related to CHIRP that, due to the structure of the program, is included in Managed Medicaid revenue.

Total Medicaid and Managed Medicaid net patient service revenues from continuing operations recognized by the hospitals and related outpatient facilities in our Hospital Operations segment for the three months ended March 31, 2022 and 2021 were $659 million and $617 million, respectively. During the three months ended March 31, 2022, Medicaid and Managed Medicaid revenues comprised 29% and 71%, respectively, of our Medicaid‑related net patient service revenues from continuing operations recognized by the hospitals and related outpatient facilities in our Hospital Operations segment. All Medicaid and Managed Medicaid patient service revenues are presented net of provider taxes or assessments paid by our hospitals, which are reported as an offset reduction to FFS Medicaid revenue.

Because we cannot predict what actions the federal government or the states may take under existing or future legislation and/or regulatory changes to address budget gaps, deficits, Medicaid expansion, provider fee programs or Medicaid Section 1115 waivers, we are unable to assess the effect that any such legislation or regulatory action might have on our business; however, the impact on our future financial position, results of operations or cash flows could be material.

### Regulatory and Legislative Changes

Material updates to the information set forth in our Annual Report about the Medicare and Medicaid payment systems, as well as other government programs impacting our business, are provided below.

*Proposed Payment and Policy Changes to the Medicare Inpatient Prospective Payment Systems—*Section 1886(d) of the Social Security Act requires CMS to update Medicare inpatient FFS payment rates for hospitals reimbursed under the inpatient prospective payment systems (“IPPS”) annually. The updates generally become effective October 1, the beginning of the federal fiscal year (“FFY”). In April 2022, CMS issued proposed changes to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and Fiscal Year 2023 Rates (“Proposed IPPS Rule”). The Proposed IPPS Rule includes the following proposed payment and policy changes:

- A market basket increase of 3.1% for Medicare severity‑adjusted diagnosis‑related group (“MS‑DRG”) operating payments for hospitals reporting specified quality measure data and that are meaningful users of electronic health record technology; CMS also proposed a 0.4% multifactor productivity reduction required by the Affordable Care Act and a 0.5% increase required by the Medicare Access and CHIP Reauthorization Act that together result in a net operating payment update of 3.2% before budget neutrality adjustments;
- Changes to the hospital Value‑Based Purchasing (“VBP”) and Hospital-Acquired Condition (“HAC”) programs for FFY 2023 due to the impact of the COVID-19 Public Health Emergency, including the implementation of a special scoring methodology for the VBP program that results in each hospital receiving a value‑based incentive payment amount equal to its 2% reduction to the operating standardized amount; and suppression of all measures in the HAC reduction program resulting in no hospitals being penalized for FFY 2023;
- An increase in the cost outlier threshold from $30,988 to $43,214;
- A 1.63% net increase in the capital federal MS‑DRG rate; and
- Updates to the three factors used to determine the amount and distribution of Medicare uncompensated care disproportionate share hospital (“UC‑DSH”) payments.

According to CMS, the combined impact of the proposed payment and policy changes in the Proposed IPPS Rule for operating costs will yield an average 1.4% increase in Medicare operating MS‑DRG FFS payments for hospitals in urban areas, and an average 2.3% increase in such payments for proprietary hospitals in FFY 2023. We estimate that all the proposed payment and policy changes affecting operating MS‑DRG and UC‑DSH payments will result in an estimated 2.3% increase in our annual Medicare FFS IPPS payments, which yields an estimated increase of approximately $45 million. Because of the uncertainty associated with various factors that may influence our future IPPS payments by individual hospital, including legislative, regulatory or legal actions, admission volumes, length of stay and case mix, as well as potential changes to the Proposed IPPS Rule, we cannot provide any assurances regarding our estimate of the impact of the proposed payment and policy changes.

*Public Health and Social Services Emergency Fund—*During the three months ended March 31, 2022 and 2021, our Hospital Operations and Ambulatory Care segments together recognized a total of $6 million and $24 million, respectively, of PRF grant income associated with lost revenues and COVID‑related costs. We also recognized $6 million of PRF grant income from our unconsolidated affiliates during the three months ended March 31, 2021. In addition to PRF grant income, our Hospital Operations and Ambulatory Care segments also recognized $7 million of grant income from state and local grant programs during the three months ended March 31, 2021. Grant income recognized by our Hospital Operations and Ambulatory Care segments is presented in grant income, and grant income recognized through our unconsolidated affiliates is presented in equity in earnings of unconsolidated affiliates, in each case in the condensed consolidated statements of operations. We cannot predict whether additional distributions of grant funds will be authorized, and we cannot provide assurances regarding the amount of grant income, if any, to be recognized in the future.

*Medicare and Medicaid Payment Policy Changes—*The federally mandated 2% sequestration reduction on Medicare FFS and Medicare Advantage payments to hospitals, physicians and other providers was suspended effective May 1, 2020 through December 31, 2021. The Protecting Medicare and American Farmers from Sequester Cuts Act (the “Sequester Cuts Act”), which was signed into law in December 2021, extended the 2% Medicare sequestration moratorium through March 31, 2022, and adjusted the sequestration to 1% for the period April 1, 2022 through June 30, 2022, after which the full 2% reduction will be restored unless further legislation is passed. The impact of the Sequester Cuts Act on our operations was an increase of approximately $20 million of revenues in the three months ended March 31, 2022, and we estimate its impact for the full year ending December 31, 2022 will be an increase of approximately $30 million of revenues. Because of the uncertainty associated with various factors that may influence our future Medicare and Medicaid payments, including future legislative, legal or regulatory actions, or changes in volumes and case mix, there is a risk that actual payments received under, or the ultimate impact of, these programs will differ materially from our expectations.

### Significant Litigation

#### 340B Litigation

The CMS 340B program allows certain hospitals (i.e., only nonprofit organizations with specific federal designations and/or funding) (“340B Hospitals”) to purchase drugs at discounted rates from drug manufacturers (“340B Drugs”). In the final rule regarding Hospital Outpatient Prospective Payment System (“OPPS”) payment and policy changes for calendar year (“CY”) 2018, CMS reduced the payment for 340B Drugs from the average sales price (“ASP”) plus 6% to the ASP minus 22.5% and made a corresponding budget‑neutral increase to payments to all hospitals for other drugs and services reimbursed under the OPPS (the “340B Payment Adjustment”). In the final rules regarding OPPS payment and policy changes for CYs 2019 through 2022, CMS continued the 340B Payment Adjustment. Certain hospital associations and hospitals commenced litigation challenging CMS’ authority to impose the 340B Payment Adjustment for CYs 2018, 2019 and 2020. Previously, the U.S. District Court for the District of Columbia (the “District Court”) held that the adoption of the 340B Payment Adjustment in the CYs 2018 and 2019 OPPS Final Rules exceeded CMS’ statutory authority by reducing drug reimbursement rates for 340B Hospitals. In July 2020, the U.S. Court of Appeals for the District of Columbia Circuit (the “Appeals Court”) reversed the District Court’s holding, finding that HHS’ decision to reduce the payment rate for 340B Drugs was based on a reasonable interpretation of the Medicare statute. The Appeals Court subsequently denied the 340B Hospitals’ petition for a rehearing. The 340B Hospitals filed a timely petition asking the U.S. Supreme Court (“Supreme Court”) to reverse the Appeals Court’s decision and, in December 2021, the Supreme Court heard oral arguments in the case. We cannot predict the timing or outcome of the Supreme Court’s decision or what further actions CMS or Congress might take with respect to the 340B program; however, a reversal of the current payment policy and return to the prior 340B payment methodology could have an adverse effect on our net operating revenues and cash flows.

### PRIVATE INSURANCE

### Managed Care

We currently have thousands of managed care contracts with various HMOs and PPOs. HMOs generally maintain a full‑service healthcare delivery network comprised of physician, hospital, pharmacy and ancillary service providers that HMO members must access through an assigned “primary care” physician. The member’s care is then managed by his or her primary care physician and other network providers in accordance with the HMO’s quality assurance and utilization review guidelines so that appropriate healthcare can be efficiently delivered in the most cost‑effective manner. HMOs typically provide reduced benefits or reimbursement (or none at all) to their members who use non‑contracted healthcare providers for non‑emergency care.

PPOs generally offer limited benefits to members who use non‑contracted healthcare providers. PPO members who use contracted healthcare providers receive a preferred benefit, typically in the form of lower co‑pays, co‑insurance or deductibles. As employers and employees have demanded more choice, managed care plans have developed hybrid products that combine elements of both HMO and PPO plans, including high‑deductible healthcare plans that may have limited benefits, but cost the employee less in premiums.

The amount of our managed care net patient service revenues, including Medicare and Medicaid managed care programs, from our hospitals and related outpatient facilities during the three months ended March 31, 2022 and 2021 was $2.495 billion and $2.480 billion, respectively. Our top 10 managed care payers generated 61% of our managed care net patient service revenues for the three months ended March 31, 2022. During the same period, national payers generated 41% of our managed care net patient service revenues; the remainder came from regional or local payers. At March 31, 2022 and December 31, 2021, 68% and 67%, respectively, of our net accounts receivable for our Hospital Operations segment were due from managed care payers.

Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per‑diem rates, discounted FFS rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a patient‑by‑patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. We believe it is reasonably likely for there to be an approximately 3% increase or decrease in the estimated contractual allowances related to managed care plans. Based on reserves at March 31, 2022, a 3% increase or decrease in the estimated contractual allowance would impact the estimated reserves by approximately $16 million. Some of the factors that can contribute to changes in the contractual allowance estimates include: (1) changes in reimbursement levels for procedures, supplies and drugs when threshold levels are triggered; (2) changes in reimbursement levels when stop‑loss or outlier limits are reached; (3) changes in the admission status of a patient due to physician orders subsequent to initial diagnosis or testing; (4) final coding of in‑house and discharged‑not‑final‑billed patients that change reimbursement levels; (5) secondary benefits determined after primary insurance payments; and (6) reclassification of patients among insurance plans with different coverage and payment levels. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues. In addition, on a corporate‑wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.

We expect managed care governmental admissions to continue to increase as a percentage of total managed care admissions over the near term. However, the managed Medicare and Medicaid insurance plans typically generate lower yields than commercial managed care plans, which have been experiencing an improved pricing trend. Although we have benefited from solid year‑over‑year aggregate managed care pricing improvements for some time, we have seen these improvements moderate in recent years, and we believe this moderation could continue into the future. In the three months ended March 31, 2022, our commercial managed care net inpatient revenue per admission from the hospitals in our Hospital Operations segment was approximately 86% higher than our aggregate yield on a per‑admission basis from government payers, including managed Medicare and Medicaid insurance plans.

### Indemnity

An indemnity‑based agreement generally requires the insurer to reimburse an insured patient for healthcare expenses after those expenses have been incurred by the patient, subject to policy conditions and exclusions. Unlike an HMO member, a patient with indemnity insurance is free to control his or her utilization of healthcare and selection of healthcare providers.

### Legislative Changes

As more fully described in Item 1, Business — Healthcare Regulation and Licensing, of Part I of our Annual Report, the No Surprises Act (“NSA”) and the rules promulgated thereunder went into effect on January 1, 2022. The NSA is intended to address unexpected gaps in insurance coverage that result in “surprise medical bills” when patients unknowingly obtain medical services from physicians and other providers outside their health insurance network, including certain emergency services, anesthesiology services and air ambulance transportation. At this time, we are unable to assess the effect that the NSA or regulations relating to the NSA might have on our business, financial position, results of operations or cash flows.

### UNINSURED PATIENTS

Uninsured patients are patients who do not qualify for government programs payments, such as Medicare and Medicaid, do not have some form of private insurance and, therefore, are responsible for their own medical bills. A significant number of our uninsured patients are admitted through our hospitals’ emergency departments and often require high‑acuity treatment that is more costly to provide and, therefore, results in higher billings, which are the least collectible of all accounts.

Self‑pay accounts receivable, which include amounts due from uninsured patients, as well as co‑pays, co‑insurance amounts and deductibles owed to us by patients with insurance, pose significant collectability problems. At March 31, 2022 and December 31, 2021, 3% and 4%, respectively, of our net accounts receivable for our Hospital Operations segment was self‑pay. Further, a significant portion of our implicit price concessions relates to self‑pay amounts. We provide revenue cycle management services through Conifer, which is subject to various statutes and regulations regarding consumer protection in areas including finance, debt collection and credit reporting activities. For additional information, see Item 1, Business — Regulations Affecting Conifer’s Operations, of Part I of our Annual Report.

Conifer has performed systematic analyses to focus our attention on the drivers of bad debt expense for each hospital. While emergency department use is the primary contributor to our implicit price concessions in the aggregate, this is not the case at all hospitals. As a result, we have increased our focus on targeted initiatives that concentrate on non‑emergency department patients as well. These initiatives are intended to promote process efficiencies in collecting self‑pay accounts, as well as co‑pay, co‑insurance and deductible amounts owed to us by patients with insurance, that we deem highly collectible. We leverage a statistical‑based collections model that aligns our operational capacity to maximize our collections performance. We are dedicated to modifying and refining our processes as needed, enhancing our technology and improving staff training throughout the revenue cycle process in an effort to increase collections and reduce accounts receivable.

Over the longer term, several other initiatives we have previously announced should also help address the challenges associated with serving uninsured patients. For example, our *Compact with Uninsured Patients (“Compact”*) is designed to offer managed care‑style discounts to certain uninsured patients, which enables us to offer lower rates to those patients who historically had been charged standard gross charges. Under the *Compact*, the discount offered to uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self‑pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for self‑pay accounts and other factors that affect the estimation process.

We also provide financial assistance through our charity and uninsured discount programs to uninsured patients who are unable to pay for the healthcare services they receive. Our policy is not to pursue collection of amounts determined to qualify for financial assistance; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid DSH payments. These payments are intended to mitigate our cost of uncompensated care. Some states have also developed provider fee or other supplemental payment programs to mitigate the shortfall of Medicaid reimbursement compared to the cost of caring for Medicaid patients.

The initial expansion of health insurance coverage under the Affordable Care Act resulted in an increase in the number of patients using our facilities with either health insurance exchange or government healthcare insurance program coverage. However, we continue to have to provide uninsured discounts and charity care due to the failure of certain states to expand Medicaid coverage and for persons living in the country who are not permitted to enroll in a health insurance exchange or government healthcare insurance program.

The following table presents our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our uninsured and charity patients.

| Estimated costs for: | Three Months Ended March 31, 2022 | 2021 |
| --- | ---: | ---: |
| Uninsured patients | $122 | $168 |
| Charity care patients | 21 | 20 |
| **Total** | **$143** | **$188** |

### RESULTS OF OPERATIONS

The following tables present our consolidated net operating revenues, operating expenses and operating income on a continuing operations basis, both in dollar amounts and as percentages of net operating revenues.

| Net operating revenues: | Three Months Ended March 31, 2022 | 2021 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Hospital Operations | $3,798 | $3,947 | $(149) |
| Ambulatory Care | 738 | 646 | 92 |
| Conifer | 324 | 310 | 14 |
| Inter-segment eliminations | (115) | (122) | 7 |
| **Net operating revenues** | **4,745** | **4,781** | **(36)** |
| **Grant income** | **6** | **31** | **(25)** |
| **Equity in earnings of unconsolidated affiliates** | **46** | **42** | **4** |
| Operating expenses: |  |  |  |
| Salaries, wages and benefits | 2,182 | 2,201 | (19) |
| Supplies | 785 | 804 | (19) |
| Other operating expenses, net | 942 | 1,072 | (130) |
| Depreciation and amortization | 203 | 224 | (21) |
| Impairment and restructuring charges, and acquisition-related costs | 16 | 20 | (4) |
| Litigation and investigation costs | 20 | 13 | 7 |
| Net losses on sales, consolidation and deconsolidation of facilities | 1 | — | 1 |
| **Operating income** | **$648** | **$520** | **$128** |

|  | Three Months Ended March 31, 2022 | 2021 | Increase (Decrease)(1) |
| --- | ---: | ---: | ---: |
| Net operating revenues | 100.0% | 100.0% | —% |
| Grant income | 0.1% | 0.6% | (0.5)% |
| Equity in earnings of unconsolidated affiliates | 1.0% | 0.9% | 0.1% |
| Operating expenses: |  |  |  |
| Salaries, wages and benefits | 46.0% | 46.0% | —% |
| Supplies | 16.5% | 16.8% | (0.3)% |
| Other operating expenses, net | 19.9% | 22.4% | (2.5)% |
| Depreciation and amortization | 4.3% | 4.7% | (0.4)% |
| Impairment and restructuring charges, and acquisition-related costs | 0.3% | 0.4% | (0.1)% |
| Litigation and investigation costs | 0.4% | 0.3% | 0.1% |
| Net losses on sales, consolidation and deconsolidation of facilities | —% | —% | —% |
| **Operating income** | **13.7%** | **10.9%** | **2.8%** |

(1) The change is the difference between the 2022 and 2021 percentages presented.

The following tables present our net operating revenues, operating expenses and operating income, both in dollar amounts and as percentages of net operating revenues, by operating segment on a continuing operations basis.

|  | Three Months Ended March 31, 2022 Hospital Operations | Ambulatory Care | Conifer |
| --- | ---: | ---: | ---: |
| **Net operating revenues** | **$3,683** | **$738** | **$324** |
| **Grant income** | **4** | **2** | **—** |
| **Equity in earnings of unconsolidated affiliates** | **4** | **42** | **—** |
| Operating expenses: |  |  |  |
| Salaries, wages and benefits | 1,820 | 194 | 168 |
| Supplies | 583 | 201 | 1 |
| Other operating expenses, net | 774 | 105 | 63 |
| Depreciation and amortization | 167 | 27 | 9 |
| Impairment and restructuring charges, and acquisition-related costs | 12 | 3 | 1 |
| Litigation and investigation costs | 8 | — | 12 |
| Net losses on sales, consolidation and deconsolidation of facilities | 1 | — | — |
| **Operating income** | **$326** | **$252** | **$70** |

|  | Three Months Ended March 31, 2022 Hospital Operations | Ambulatory Care | Conifer |
| --- | ---: | ---: | ---: |
| Net operating revenues | 100.0% | 100.0% | 100.0% |
| Grant income | 0.1% | 0.3% | —% |
| Equity in earnings of unconsolidated affiliates | 0.1% | 5.7% | —% |
| Operating expenses: |  |  |  |
| Salaries, wages and benefits | 49.4% | 26.3% | 51.9% |
| Supplies | 15.8% | 27.2% | 0.3% |
| Other operating expenses, net | 21.1% | 14.3% | 19.4% |
| Depreciation and amortization | 4.5% | 3.7% | 2.8% |
| Impairment and restructuring charges, and acquisition-related costs | 0.3% | 0.4% | 0.3% |
| Litigation and investigation costs | 0.2% | —% | 3.7% |
| Net losses on sales, consolidation and deconsolidation of facilities | —% | —% | —% |
| **Operating income** | **8.9%** | **34.1%** | **21.6%** |

|  | Three Months Ended March 31, 2021 Hospital Operations | Ambulatory Care | Conifer |
| --- | ---: | ---: | ---: |
| **Net operating revenues** | **$3,825** | **$646** | **$310** |
| **Grant income** | **24** | **7** | **—** |
| **Equity in earnings of unconsolidated affiliates** | **4** | **38** | **—** |
| Operating expenses: |  |  |  |
| Salaries, wages and benefits | 1,857 | 174 | 170 |
| Supplies | 646 | 157 | 1 |
| Other operating expenses, net | 916 | 103 | 53 |
| Depreciation and amortization | 190 | 25 | 9 |
| Impairment and restructuring charges, and acquisition-related costs | 10 | 4 | 6 |
| Litigation and investigation costs | 9 | 3 | 1 |
| **Operating income** | **$225** | **$225** | **$70** |

39

|  | Three Months Ended March 31, 2021 Hospital Operations | Ambulatory Care | Conifer |
| --- | ---: | ---: | ---: |
| Net operating revenues | 100.0% | 100.0% | 100.0% |
| Grant income | 0.6% | 1.1% | —% |
| Equity in earnings of unconsolidated affiliates | 0.1% | 5.9% | —% |
| Operating expenses: |  |  |  |
| Salaries, wages and benefits | 48.5% | 26.9% | 54.8% |
| Supplies | 16.9% | 24.3% | 0.3% |
| Other operating expenses, net | 23.9% | 16.0% | 17.2% |
| Depreciation and amortization | 5.0% | 3.9% | 2.9% |
| Impairment and restructuring charges, and acquisition-related costs | 0.3% | 0.6% | 1.9% |
| Litigation and investigation costs | 0.2% | 0.5% | 0.3% |
| **Operating income** | **5.9%** | **34.8%** | **22.6%** |

Total net operating revenues decreased by $36 million, or 0.8%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. Hospital Operations net operating revenues, net of inter‑segment eliminations, decreased by $142 million, or 3.7%, for the three months ended March 31, 2022 compared to the same period in 2021. These decreases were primarily due to the sale of the Miami Hospitals and lower patient volumes, partially offset by high patient acuity and negotiated commercial rate increases. Our Hospital Operations segment also recognized income from federal grants totaling $4 million during the three months ended March 31, 2022, which is not included in net operating revenues.

Ambulatory Care net operating revenues increased by $92 million, or 14.2%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. The change was driven by an increase from acquisitions of $91 million, as well as an increase in same‑facility net operating revenues of $52 million due primarily to higher surgical patient volumes and negotiated commercial rate increases in the 2022 period. These increases were also partially offset by a decrease of $51 million due primarily to the sale of the Ambulatory Care segment’s urgent care centers and the transfer of its imaging centers to the Hospital Operations segment. Our Ambulatory Care segment also recognized income from federal grants totaling $2 million during the three months ended March 31, 2022, which is not included in net operating revenues.

Conifer’s net operating revenues increased by $14 million, or 4.5%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. Conifer’s revenues from third‑party clients, which revenues are not eliminated in consolidation, increased $21 million, or 11.2%, for the three months ended March 31, 2022 compared to the same period in 2021. This increase was primarily due to contractual rate increases, new business expansion and the transition of the Miami Hospitals to third‑party clients.

The following table presents selected operating expenses of our three operating segments. Information for our Hospital Operations segment is presented on a same‑hospital basis, whereas information presented for our Ambulatory Care and Conifer segments is presented on a continuing operations basis.

| Selected Operating Expenses Hospital Operations — Same-Hospital: | Three Months Ended March 31, 2022 | 2021 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Salaries, wages and benefits | $1,812 | $1,742 | 4.0% |
| Supplies | 581 | 603 | (3.6)% |
| Other operating expenses | 761 | 843 | (9.7)% |
| **Total** | **$3,154** | **$3,188** | **(1.1)%** |
| **Ambulatory Care:** |  |  |  |
| Salaries, wages and benefits | $194 | $174 | 11.5% |
| Supplies | 201 | 157 | 28.0% |
| Other operating expenses | 105 | 103 | 1.9% |
| **Total** | **$500** | **$434** | **15.2%** |
| **Conifer:** |  |  |  |
| Salaries, wages and benefits | $168 | $170 | (1.2)% |
| Supplies | 1 | 1 | —% |
| Other operating expenses | 63 | 53 | 18.9% |
| **Total** | **$232** | **$224** | **3.6%** |
| **Rent/lease expense(1):** |  |  |  |
| Hospital Operations | $68 | $72 | (5.6)% |
| Ambulatory Care | 27 | 27 | —% |
| Conifer | 3 | 3 | —% |
| **Total** | **$98** | **$102** | **(3.9)%** |

(1) Included in other operating expenses.

### RESULTS OF OPERATIONS BY SEGMENT

Our operations are reported in three segments:

- Hospital Operations, which is comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro‑hospitals and physician practices;
- Ambulatory Care, which is comprised of USPI’s ASCs and surgical hospitals; and
- Conifer, which provides revenue cycle management and value‑based care services to hospitals, health systems, physician practices, employers and other clients.

### Hospital Operations Segment

The following tables present operating statistics, revenues and expenses of our hospitals and related outpatient facilities on a same‑hospital basis, unless otherwise indicated.

| Admissions, Patient Days and Surgeries | Same-Hospital Three Months Ended March 31, 2022 | 2021 | Increase (Decrease) |  |
| --- | ---: | ---: | ---: | ---: |
| Number of hospitals (at end of period) | 60 | 60 | — | (1) |
| Total admissions | 127,782 | 134,120 | (4.7)% |  |
| Adjusted patient admissions(2) | 227,933 | 231,273 | (1.4)% |  |
| Paying admissions (excludes charity and uninsured) | 121,797 | 127,005 | (4.1)% |  |
| Charity and uninsured admissions | 5,985 | 7,115 | (15.9)% |  |
| Admissions through emergency department | 97,684 | 100,847 | (3.1)% |  |
| Paying admissions as a percentage of total admissions | 95.3% | 94.7% | 0.6% | (1) |
| Charity and uninsured admissions as a percentage of total admissions | 4.7% | 5.3% | (0.6)% | (1) |
| Emergency department admissions as a percentage of total admissions | 76.4% | 75.2% | 1.2% | (1) |
| Surgeries — inpatient | 32,908 | 34,096 | (3.5)% |  |
| Surgeries — outpatient | 51,258 | 50,275 | 2.0% |  |
| Total surgeries | 84,166 | 84,371 | (0.2)% |  |
| Patient days — total | 705,623 | 731,525 | (3.5)% |  |
| Adjusted patient days(2) | 1,224,824 | 1,225,520 | (0.1)% |  |
| Average length of stay (days) | 5.52 | 5.45 | 1.3% |  |
| Licensed beds (at end of period) | 15,395 | 15,403 | (0.1)% |  |
| Average licensed beds | 15,395 | 15,403 | (0.1)% |  |
| Utilization of licensed beds(3) | 50.9% | 52.8% | (1.9)% | (1) |

(1) The change is the difference between the 2022 and 2021 amounts presented.

(2) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

(3) Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

| Outpatient Visits | Same-Hospital Three Months Ended March 31, 2022 | 2021 | Increase (Decrease) |  |
| --- | ---: | ---: | ---: | ---: |
| Total visits | 1,240,386 | 1,222,696 | 1.4% |  |
| Paying visits (excludes charity and uninsured) | 1,165,718 | 1,147,511 | 1.6% |  |
| Charity and uninsured visits | 74,668 | 75,185 | (0.7)% |  |
| Emergency department visits | 500,665 | 424,361 | 18.0% |  |
| Surgery visits | 51,258 | 50,275 | 2.0% |  |
| Paying visits as a percentage of total visits | 94.0% | 93.9% | 0.1% | (1) |
| Charity and uninsured visits as a percentage of total visits | 6.0% | 6.1% | (0.1)% | (1) |

(1) The change is the difference between the 2022 and 2021 amounts presented.

| Revenues | Same-Hospital Three Months Ended March 31, 2022 | 2021 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Total segment net operating revenues(1) | $3,652 | $3,561 | 2.6% |
| **Selected revenue data – hospitals and related outpatient facilities:** |  |  |  |
| Net patient service revenues(1)(2) | $3,478 | $3,392 | 2.5% |
| Net patient service revenue per adjusted patient admission(1)(2) | $15,259 | $14,667 | 4.0% |
| Net patient service revenue per adjusted patient day(1)(2) | $2,840 | $2,768 | 2.6% |

(1) Revenues are net of implicit price concessions.

(2) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

| Total Segment Selected Operating Expenses | Same-Hospital Three Months Ended March 31, 2022 | 2021 | Increase (Decrease)(1) |
| --- | ---: | ---: | ---: |
| Salaries, wages and benefits as a percentage of net operating revenues | 49.6% | 48.9% | 0.7% |
| Supplies as a percentage of net operating revenues | 15.9% | 16.9% | (1.0)% |
| Other operating expenses as a percentage of net operating revenues | 20.8% | 23.7% | (2.9)% |

(1) The change is the difference between the 2022 and 2021 amounts presented.

#### Revenues

Same‑hospital net operating revenues increased $91 million, or 2.6%, during the three months ended March 31, 2022 compared to the three months ended March 31, 2021, primarily due to high patient acuity and negotiated commercial rate increases. Our Hospital Operations segment also recognized grant income totaling $4 million and $24 million from federal, state and local grants in the three months ended March 31, 2022 and 2021, respectively, which is not included in net operating revenues. Same‑hospital admissions decreased 4.7% in the three months ended March 31, 2022 compared to the same period in 2021, primarily due to the impact of the Omicron variant in January and February 2022.

The following table presents the consolidated net accounts receivable by payer at March 31, 2022 and December 31, 2021:

|  | March 31, 2022 | December 31, 2021 |
| --- | ---: | ---: |
| Medicare | $150 | $155 |
| Medicaid | 50 | 47 |
| Net cost report settlements receivable and valuation allowances | 16 | 33 |
| Managed care | 1,751 | 1,602 |
| Self-pay uninsured | 18 | 21 |
| Self-pay balance after insurance | 69 | 70 |
| Estimated future recoveries | 139 | 137 |
| Other payers | 373 | 331 |
| Total Hospital Operations | 2,566 | 2,396 |
| Ambulatory Care | 350 | 374 |
| **Accounts receivable, net** | **$2,916** | **$2,770** |

Collection of accounts receivable has been a key area of focus, particularly over the past several years. At March 31, 2022, our Hospital Operations segment collection rate on self‑pay accounts was approximately 27.2%. Our self‑pay collection rate includes payments made by patients, including co‑pays, co‑insurance amounts and deductibles paid by patients with insurance. Based on our accounts receivable from uninsured patients and co‑pays, co‑insurance amounts and deductibles owed to us by patients with insurance at March 31, 2022, a 10% decrease or increase in our self‑pay collection rate, or approximately 3%, which we believe could be a reasonably likely change, would result in an unfavorable or favorable adjustment to patient accounts receivable of approximately $9 million. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients, the volume of patients through our emergency departments, the increased burden of co‑pays and deductibles to be made by patients with insurance, and business practices related to collection efforts. These factors, many of which have been affected by the COVID‑19 pandemic, continuously change and can have an impact on collection trends and our estimation process.

We also typically experience ongoing managed care payment delays and disputes; however, we continue to work with these payers to obtain adequate and timely reimbursement for our services. Our estimated Hospital Operations segment collection rate from managed care payers was approximately 96.3% at March 31, 2022.

We manage our implicit price concessions using hospital‑specific goals and benchmarks such as (1) total cash collections, (2) point‑of‑service cash collections, (3) AR Days and (4) accounts receivable by aging category. The following tables present the approximate aging by payer of our net accounts receivable from the continuing operations of our Hospital Operations segment of $2.550 billion and $2.363 billion at March 31, 2022 and December 31, 2021, respectively, excluding cost report settlements receivable and valuation allowances of $16 million and $33 million, respectively, at March 31, 2022 and December 31, 2021:

| At March 31, 2022: | Medicare | Medicaid | Managed Care | Indemnity, Self-Pay and Other | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| 0-60 days | 91% | 32% | 56% | 23% | 50% |
| 61-120 days | 4% | 29% | 16% | 14% | 15% |
| 121-180 days | 2% | 16% | 10% | 9% | 10% |
| Over 180 days | 3% | 23% | 18% | 54% | 25% |
| **Total** | **100%** | **100%** | **100%** | **100%** | **100%** |
| **At December 31, 2021:** |  |  |  |  |  |
| 0-60 days | 93% | 35% | 57% | 22% | 52% |
| 61-120 days | 4% | 31% | 18% | 14% | 16% |
| 121-180 days | 1% | 14% | 10% | 9% | 9% |
| Over 180 days | 2% | 20% | 15% | 55% | 23% |
| **Total** | **100%** | **100%** | **100%** | **100%** | **100%** |

Conifer continues to implement revenue cycle initiatives to improve our cash flow. These initiatives are focused on standardizing and improving patient access processes, including pre‑registration, registration, verification of eligibility and benefits, liability identification and collections at point‑of‑service, and financial counseling. These initiatives are intended to reduce denials, improve service levels to patients and increase the quality of accounts that end up in accounts receivable. Although we continue to focus on improving our methodology for evaluating the collectability of our accounts receivable, we may incur future charges if there are unfavorable changes in the trends affecting the net realizable value of our accounts receivable.

At March 31, 2022, we had a cumulative total of patient account assignments to Conifer of $1.911 billion related to our continuing operations. These accounts have already been written off and are not included in our receivables; however, an estimate of future recoveries from all the accounts assigned to Conifer is determined based on our historical experience and recorded in accounts receivable.

Patient advocates from Conifer’s Eligibility and Enrollment Services program (“EES”) screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs. Receivables from patients who are potentially eligible for Medicaid are classified as Medicaid pending, under the EES, net of appropriate implicit price concessions. Based on recent trends, approximately 97% of all accounts in the EES are ultimately approved for benefits under a government program, such as Medicaid.

The following table presents the approximate amount of accounts receivable in the EES still awaiting determination of eligibility under a government program at March 31, 2022 and December 31, 2021 by aging category:

|  | March 31, 2022 | December 31, 2021 |
| --- | ---: | ---: |
| 0-60 days | $75 | $87 |
| 61-120 days | 18 | 17 |
| 121-180 days | 4 | 4 |
| Over 180 days | 9 | 7 |
| **Total** | **$106** | **$115** |

#### Salaries, Wages and Benefits

Same‑hospital salaries, wages and benefits increased $70 million, or 4%, in the three months ended March 31, 2022 compared to the same period in 2021. This increase was primarily attributable to increased contract labor and overtime costs, partially offset by our cost-efficiency measures, including the use of labor management tools as patient volumes fluctuate. Same‑hospital salaries, wages and benefits as a percentage of net operating revenues increased by 70 basis points to 49.6% in the three months ended March 31, 2022 compared to the three months ended March 31, 2021, primarily due to the factors described above. Salaries, wages and benefits expense for the three months ended March 31, 2022 and 2021 included stock‑based compensation expense of $12 million and $10 million, respectively.

#### Supplies

Same‑hospital supplies expense decreased $22 million, or 3.6%, in the three months ended March 31, 2022 compared to the same period in 2021. The decrease was primarily due to our cost-efficiency measures, including those described below, and lower patient volumes, partially offset by the increased cost of certain supplies as a result of the COVID‑19 pandemic and growth in our higher‑acuity, supply‑intensive surgical services. Same‑hospital supplies expense as a percentage of net operating revenues decreased by 100 basis points to 15.9% in the three months ended March 31, 2022 compared to the three months ended March 31, 2021, primarily due to our continued focus on strategic cost-efficiency measures. We strive to control supplies expense through product standardization, consistent contract terms and end‑to‑end contract management, improved utilization, bulk purchases, focused spending with a smaller number of vendors and operational improvements.

#### Other Operating Expenses, Net

Same‑hospital other operating expenses decreased by $82 million, or 9.7%, in the three months ended March 31, 2022 compared to the same period in 2021. The changes in other operating expenses included:

- a gain on the sale of several medical office buildings of $69 million; and
- decreased medical expenses of $11 million.

Same‑hospital other operating expenses as a percentage of net operating revenues decreased by 290 basis points to 20.8% for the three months ended March 31, 2022 compared to 23.7% for the three months ended March 31, 2021, primarily due to the gain recognized on the sale of several medical office buildings during the 2022 period and our continued focus on cost-efficiency measures.

### Ambulatory Care Segment

Our Ambulatory Care segment is comprised of USPI’s ASCs and surgical hospitals. USPI operates its surgical facilities in partnership with local physicians and, in many of these facilities, a health system partner. We hold an ownership interest in each facility, with each being operated through a separate legal entity in most cases. USPI operates facilities on a day‑to‑day basis through management services contracts. Our sources of earnings from each facility consist of:

- management and administrative services revenues, computed as a percentage of each facility’s net revenues (often net of implicit price concessions); and
- our share of each facility’s net income (loss), which is computed by multiplying the facility’s net income (loss) times the percentage of each facility’s equity interests owned by USPI.

Our role as an owner and day‑to‑day manager provides us with significant influence over the operations of each facility. For many of the facilities our Ambulatory Care segment operates (167 of 428 facilities at March 31, 2022), this influence does not represent control of the facility, so we account for our investment in the facility under the equity method for an unconsolidated affiliate. USPI controls 261 of the facilities our Ambulatory Care segment operates, and we account for these investments as consolidated subsidiaries. Our net earnings from a facility are the same under either method, but the classification of those earnings differs. For consolidated subsidiaries, our financial statements reflect 100% of the revenues and expenses of the subsidiaries, after the elimination of intercompany amounts. The net profit attributable to owners other than USPI is classified within net income available to noncontrolling interests.

For unconsolidated affiliates, our statements of operations reflect our earnings in two line items:

- *equity in earnings of unconsolidated affiliates—*our share of the net income (loss) of each facility, which is based on the facility’s net income (loss) and the percentage of the facility’s outstanding equity interests owned by USPI; and
- *management and administrative services revenues, which is included in our net operating revenues—*income we earn in exchange for managing the day‑to‑day operations of each facility, usually quantified as a percentage of each facility’s net revenues less implicit price concessions.

Our Ambulatory Care segment operating income is driven by the performance of all facilities USPI operates and by USPI’s ownership interests in those facilities, but our individual revenue and expense line items contain only consolidated businesses, which represent 61% of those facilities. This translates to trends in consolidated operating income that often do not correspond with changes in consolidated revenues and expenses, which is why we disclose certain statistical and financial data on a pro forma systemwide basis that includes both consolidated and unconsolidated (equity method) facilities.

#### Results of Operations

The following table summarizes certain statement of operations items for the periods indicated:

| Ambulatory Care Results of Operations | Three Months Ended March 31, 2022 | 2021 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Net operating revenues | $738 | $646 | 14.2% |
| Grant income | $2 | $7 | (71.4)% |
| Equity in earnings of unconsolidated affiliates | $42 | $38 | 10.5% |
| Salaries, wages and benefits | $194 | $174 | 11.5% |
| Supplies | $201 | $157 | 28.0% |
| Other operating expenses, net | $105 | $103 | 1.9% |

#### Revenues

Ambulatory Care net operating revenues increased by $92 million, or 14.2%, during the three months ended March 31, 2022 compared to the same period in 2021. The change was driven by an increase from acquisitions of $91 million, as well as an increase in same‑facility net operating revenues of $52 million due primarily to higher surgical patient volumes and negotiated commercial rate increases. These increases were also partially offset by a decrease of $51 million due primarily to the sale of the Ambulatory Care segment’s urgent care centers and the transfer of its imaging centers to the Hospital Operations segment. Our Ambulatory Care segment also recognized income from federal grants totaling $2 million and $7 million during the three months ended March 31, 2022 and 2021, respectively, which is not included in net operating revenues.

#### Salaries, Wages and Benefits

Salaries, wages and benefits expense increased by $20 million, or 11.5%, during the three months ended March 31, 2022 compared to the same period in 2021. Salaries, wages and benefits expense was impacted by an increase from acquisitions of $26 million, as well as an increase in same‑facility salaries, wages and benefits expense of $17 million due primarily to higher surgical patient volumes. These increases were partially offset by a decrease of $23 million due primarily to the sale of the Ambulatory Care segment’s urgent care centers and the transfer of its imaging centers to the Hospital Operations segment. Salaries, wages and benefits expense for three months ended March 31, 2022 and 2021 included stock‑based compensation expense of $3 million in both periods.

#### Supplies

Supplies expense increased by $44 million, or 28.0%, during the three months ended March 31, 2022 compared to the same period in 2021. The change was driven by an increase from acquisitions of $32 million, as well as an increase in same‑facility supplies expense of $15 million due primarily to an increase in surgical patient volumes and higher pricing of certain supplies as a result of the COVID‑19 pandemic, partially offset by a decrease of $3 million due to the sale of the Ambulatory Care segment’s urgent care centers and the transfer of its imaging centers to the Hospital Operations segment.

#### Other Operating Expenses, Net

Other operating expenses increased by $2 million, or 1.9%, during the three months ended March 31, 2022 compared to the same period in 2021. The change was driven by an increase from acquisitions of $12 million, as well as an increase in same‑facility other operating expenses of $5 million, partially offset by a decrease of $15 million due to the sale of the Ambulatory Care segment’s urgent care centers and the transfer of its imaging centers to the Hospital Operations segment.

#### Facility Growth

The following table summarizes the year‑over‑year changes in our same‑facility revenue for the three‑month periods ended March 31, 2022 and 2021 on a pro forma systemwide basis, which includes both consolidated and unconsolidated (equity method) facilities. While we do not record the revenues of unconsolidated facilities, we believe this information is important in understanding the financial performance of our Ambulatory Care segment because these revenues are the basis for calculating our management services revenues and, together with the expenses of our unconsolidated facilities, are the basis for our equity in earnings of unconsolidated affiliates.

| Ambulatory Care Facility Growth | Three Months Ended March 31, 2022 |
| --- | ---: |
| Net revenues | 9.3% |
| Cases | 8.0% |
| Net revenue per case | 1.1% |

#### Joint Ventures with Health System Partners

USPI’s business model is to jointly own its facilities with local physicians and, in many of these facilities, a not‑for‑profit health system partner. Accordingly, as of March 31, 2022, the majority of facilities in our Ambulatory Care segment are operated in this model.

The table below summarizes the amounts we paid to acquire various ownership interests in ambulatory care facilities in the periods indicated:

| Type of Ownership Interests Acquired | Three Months Ended March 31, 2022 | 2021 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Controlling interests | $40 | $24 | $16 |
| Equity investment in unconsolidated affiliates and consolidated facilities | 9 | 1 | 8 |
| **Total** | **$49** | **$25** | **$24** |

The table below provides information about the ownership structure of the facilities our Ambulatory Care segment operated at March 31, 2022:

| Ambulatory Care Facilities Ownership Structure: | March 31, 2022 |
| --- | ---: |
| With a health system partner | 198 |
| Without a health system partner | 230 |
| **Total facilities operated** | **428** |

47

The table below reflects changes in the number of ambulatory care facilities during the three months ended March 31, 2022:

| Ambulatory Care Facilities Change from December 31, 2021: | Three Months Ended March 31, 2022 |
| --- | ---: |
| Acquisitions | 4 |
| De novo | 2 |
| Dispositions/Mergers | (1) |
| **Total increase in number of facilities operated** | **5** |

During the three months ended March 31, 2022, we acquired controlling interests in two ASCs located in Florida and one in New Hampshire. We paid cash totaling $31 million for these acquisitions, which are jointly owned with physicians. During the same period in 2022, we acquired a noncontrolling interest in an ASC located in New Jersey.

Also during the three months ended March 31, 2022, we acquired controlling interests in three previously unconsolidated SCD Centers, located in Florida, Pennsylvania and Texas, for $9 million. Following our acquisition of a controlling interest in the Texas ASC, we contributed our ownership interest in it to our subsidiary Texas Health Ventures Group, L.L.C.

We also regularly engage in the purchase of equity interests with respect to our investments in unconsolidated affiliates and consolidated facilities that do not result in a change in control. These transactions are primarily the acquisitions of equity interests in ASCs and the investment of additional cash in facilities that need capital for new acquisitions, new construction or other business growth opportunities. During the three months ended March 31, 2022, we invested approximately $9 million in such transactions.

### Conifer Segment

#### Revenues

Our Conifer segment generated net operating revenues of $324 million and $310 million during the three months ended March 31, 2022 and 2021, respectively, a portion of which was eliminated in consolidation as described in Note 18 to the accompanying Condensed Consolidated Financial Statements. The increase in Conifer’s net operating revenues was $14 million, or 4.5%. Conifer’s revenues from third‑party clients, which revenues are not eliminated in consolidation, increased $21 million, or 11.2%, for the three months ended March 31, 2022 compared to the same period in 2021. The increase was primarily attributable to contractual rate increases, new business expansion and the transition of the Miami Hospitals to third‑party clients in the 2022 period.

#### Salaries, Wages and Benefits

Salaries, wages and benefits expense for Conifer decreased $2 million, or 1.2%, in the three months ended March 31, 2022 compared to the same period in 2021. The decrease was primarily due cost-efficiency measures and lower incentive compensation in 2022. Salaries, wages and benefits expense included stock‑based compensation expense of $1 million in each of the three‑month periods ended March 31, 2022 and 2021.

#### Other Operating Expenses, Net

Other operating expenses for Conifer increased $10 million, or 18.9%, in the three months ended March 31, 2022 compared to the same period in 2021. This increase was primarily due to higher vendor fee and recruiting expenses in 2022.

### Consolidated

#### Impairment and Restructuring Charges, and Acquisition-Related Costs

The following table presents information about our impairment and restructuring charges, and acquisition‑related costs:

| Consolidated: | Three Months Ended March 31, 2022 | 2021 |
| --- | ---: | ---: |
| Impairment charges | $1 | $— |
| Restructuring charges | 12 | 16 |
| Acquisition-related costs | 3 | 4 |
| **Total impairment and restructuring charges, and acquisition-related costs** | **$16** | **$20** |
| **By segment:** |  |  |
| Hospital Operations | $12 | $10 |
| Ambulatory Care | 3 | 4 |
| Conifer | 1 | 6 |
| **Total impairment and restructuring charges, and acquisition-related costs** | **$16** | **$20** |

During the three months ended March 31, 2022, restructuring charges consisted of $5 million of employee severance costs, $2 million related to the transition of various administrative functions to our GBC and $5 million of other restructuring costs. Acquisition‑related costs consisted of $3 million of transaction costs.

During the three months ended March 31, 2021, restructuring charges consisted of $4 million of employee severance costs, $6 million related to the transition of various administrative functions to our GBC and $6 million of other restructuring costs. Acquisition‑related costs consisted of $4 million of transaction costs.

#### Litigation and Investigation Costs

Litigation and investigation costs for the three months ended March 31, 2022 and 2021 were $20 million and $13 million, respectively.

#### Interest Expense

Interest expense for the three months ended March 31, 2022 was $227 million compared to $240 million for the same period in 2021.

#### Loss from Early Extinguishment of Debt

During the three months ended March 31, 2022, we incurred aggregate losses from the early extinguishment of debt of $43 million. These losses related to the redemption of our 2025 Senior Secured First Lien Notes in advance of their maturity date and the repurchase of $103 million aggregate principal amount outstanding of our 2023 Senior Unsecured Notes. The losses incurred from these transactions primarily related to the difference between the purchase prices and the par value of the notes, as well as the write‑off of associated unamortized issuance costs.

Loss from early extinguishment of debt was $23 million for the three months ended March 31, 2021 and related to the retirement of our 7.000% senior unsecured notes due 2025 in advance of their maturity date.

#### Income Tax Expense

During the three months ended March 31, 2022, we recorded income tax expense of $99 million in continuing operations on pre-tax income of $378 million compared to $45 million on pre-tax income of $267 million during the prior‑year period. During the three months ended March 31, 2022, we recorded income tax expense of $32 million to increase the valuation allowance for interest expense carryforwards due to a change in the business interest expense disallowance rules in 2022.

A reconciliation between the amount of reported income tax expense and the amount computed by multiplying income from continuing operations before income taxes by the statutory federal tax rate is presented below:

|  | Three Months Ended March 31, 2022 | 2021 |
| --- | ---: | ---: |
| Tax expense at statutory federal rate of 21% | $79 | $56 |
| State income taxes, net of federal income tax benefit | 14 | 13 |
| Tax benefit attributable to noncontrolling interests | (29) | (25) |
| Stock-based compensation tax benefit | (2) | (1) |
| Changes in valuation allowance | 32 | — |
| Other items | 5 | 2 |
| **Income tax expense** | **$99** | **$45** |

#### Net Income Available to Noncontrolling Interests

Net income available to noncontrolling interests was $140 million for the three months ended March 31, 2022 compared to $125 million for the three months ended March 31, 2021. Net income available to noncontrolling interests for the 2022 period was comprised of $99 million related to our Ambulatory Care segment, $25 million related to our Hospital Operations segment, which was substantially due to our Alabama joint venture partner’s share of the $69 million gain from the sale of several medical office buildings, and $16 million related to our Conifer segment. Of the portion related to our Ambulatory Care segment, $4 million related to the minority interests in USPI.

### ADDITIONAL SUPPLEMENTAL NON-GAAP DISCLOSURES

The financial information provided throughout this report, including our Condensed Consolidated Financial Statements and the notes thereto, has been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). However, we use certain non‑GAAP financial measures defined below in communications with investors, analysts, rating agencies, banks and others to assist such parties in understanding the impact of various items on our financial statements, some of which are recurring or involve cash payments. We use this information in our analysis of the performance of our business, excluding items we do not consider relevant to the performance of our continuing operations. In addition, we use these measures to define certain performance targets under our compensation programs.

“Adjusted EBITDA” is a non‑GAAP measure we define as net income available (loss attributable) to Tenet Healthcare Corporation common shareholders before (1) the cumulative effect of changes in accounting principle, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non‑operating income (expense), net, (7) interest expense, (8) litigation and investigation (costs) benefit, net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition‑related costs, (11) depreciation and amortization, and (12) income (loss) from divested and closed businesses (i.e., health plan businesses). Litigation and investigation costs do not include ordinary course of business malpractice and other litigation and related expense.

We believe the foregoing non‑GAAP measure is useful to investors and analysts because it presents additional information about our financial performance. Investors, analysts, company management and our board of directors utilize this non‑GAAP measure, in addition to GAAP measures, to track our financial and operating performance and compare that performance to peer companies, which utilize similar non‑GAAP measures in their presentations. The human resources committee of our board of directors also uses certain non‑GAAP measures to evaluate management’s performance for the purpose of determining incentive compensation. We believe that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to GAAP and other non‑GAAP measures, as factors in determining the estimated fair value of shares of our common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. We do not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance. The non‑GAAP Adjusted EBITDA measure we utilize may not be comparable to similarly titled measures reported by other companies. Because this measure excludes many items that are included in our financial statements, it does not provide a complete measure of our operating performance. Accordingly, investors are encouraged to use GAAP measures when evaluating our financial performance.

The following table presents the reconciliation of Adjusted EBITDA to net income available to Tenet Healthcare Corporation common shareholders (the most comparable GAAP term) for the three months ended March 31, 2022 and 2021:

|  | Three Months Ended March 31, 2022 | 2021 |
| --- | ---: | ---: |
| **Net income available to Tenet Healthcare Corporation common shareholders** | **$140** | **$97** |
| Less: Net income available to noncontrolling interests | (140) | (125) |
| Income from discontinued operations, net of tax | 1 | — |
| Income from continuing operations | 279 | 222 |
| Income tax expense | (99) | (45) |
| Loss from early extinguishment of debt | (43) | (23) |
| Other non-operating income, net | — | 10 |
| Interest expense | (227) | (240) |
| Operating income | 648 | 520 |
| Litigation and investigation costs | (20) | (13) |
| Net losses on sales, consolidation and deconsolidation of facilities | (1) | — |
| Impairment and restructuring charges, and acquisition-related costs | (16) | (20) |
| Depreciation and amortization | (203) | (224) |
| **Adjusted EBITDA** | **$888** | **$777** |
| **Net operating revenues** | **$4,745** | **$4,781** |
| **Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues** | **3.0%** | **2.0%** |
| **Adjusted EBITDA as % of net operating revenues (Adjusted EBITDA margin)** | **18.7%** | **16.3%** |

### LIQUIDITY AND CAPITAL RESOURCES

### CASH REQUIREMENTS

### Scheduled Contractual Obligations

There have been no material changes to our obligations to make future cash payments under scheduled contractual obligations, such as debt and lease agreements, and under contingent commitments, such as standby letters of credit and minimum revenue guarantees, as disclosed in our Annual Report, except for the matters described below and the additional lease obligations and the long‑term debt transactions disclosed in Notes 1 and 6, respectively, to our accompanying Condensed Consolidated Financial Statements.

At March 31, 2022, using the last 12 months of Adjusted EBITDA, our ratio of total long‑term debt, net of cash and cash equivalent balances, to Adjusted EBITDA was 3.74x, or 3.93x if adjusted to include outstanding obligations arising from cash advances received from Medicare pursuant to COVID‑19 relief legislation. We anticipate this ratio will fluctuate from quarter to quarter based on earnings performance and other factors, including the use of our Credit Agreement as a source of liquidity and acquisitions that involve the assumption of long‑term debt. We seek to manage this ratio and increase the efficiency of our balance sheet by following our business plan and managing our cost structure, including through possible asset divestitures, and through other changes in our capital structure. As part of our long‑term objective to manage our capital structure, we continue to evaluate opportunities to retire, purchase, redeem and refinance outstanding debt subject to prevailing market conditions, our liquidity requirements, operating results, contractual restrictions and other factors. In the year ending December 31, 2023 and beyond, we may also consider share repurchases depending on market conditions and other investment opportunities. Our ability to achieve our leverage and capital structure objectives is subject to numerous risks and uncertainties, many of which are described in the Forward‑Looking Statements and Risk Factors sections in Part I of our Annual Report and the Risk Factors section in Part II of this report.

Interest payments, net of capitalized interest, were $166 million and $190 million in the three months ended March 31, 2022 and 2021, respectively.

### Other Contractual Obligations

*Baylor Put/Call Agreement—*As previously discussed in our Annual Report, we have a put/call agreement with Baylor University Medical Center (“Baylor”) with respect to Baylor’s 5% ownership in USPI. Each year starting in 2021, Baylor may put up to one‑third of its total shares in USPI (the “Baylor Shares”) by delivering notice by the end of January of such year. In each year that Baylor does not put the full 33.3% of USPI’s shares allowable, we may call the difference between the number of shares Baylor put and the maximum number of shares it could have put that year. We have the ability to choose whether to settle the purchase price for the Baylor put/call, which is mutually agreed‑upon fair market value, in cash or shares of our common stock.

Baylor did not deliver a put notice to us in January 2021 or 2022. In each of February 2021 and 2022, we notified Baylor of our intention to exercise our call option to purchase 33.3% of the Baylor Shares for that year (now 66.6% in total). We are continuing to negotiate the terms of those purchases. We expect that the estimated payment to repurchase the shares called in February 2021 and 2022 will be at least $250 million in the aggregate based on an increase in the estimated fair value of USPI.

*Investment in the SCD Centers—*USPI continues to make offers in an ongoing process to acquire a portion of the equity interests in certain of the SCD Centers from the physician owners for consideration of up to approximately $250 million. During the three months ended March 31, 2022, we made aggregate payments of $9 million to acquire controlling interests in three SCD Centers. We cannot reasonably predict how many additional physician owners will accept our offers to acquire a portion of their equity, nor the timing or amount of any remaining payments. We expect to fund these payments using cash on hand.

We have no off-balance sheet arrangements that may have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for $247 million of standby letters of credit outstanding and guarantees at March 31, 2022.

### Other Cash Requirements

Our capital expenditures primarily relate to the expansion and renovation of existing facilities (including amounts to comply with applicable laws and regulations), equipment and information systems additions and replacements, introduction of new medical technologies, design and construction of new buildings or hospitals, and various other capital improvements, as well as commitments to make capital expenditures in connection with acquisitions of businesses. Capital expenditures were $155 million and $121 million in the three months ended March 31, 2022 and 2021, respectively. We anticipate that our capital expenditures for continuing operations for the year ending December 31, 2022 will total approximately $725 million to $775 million, including $95 million that was accrued as a liability at December 31, 2021.

Income tax payments, net of tax refunds, were $8 million in the three months ended March 31, 2022 compared to $2 million in the three months ended March 31, 2021.

### SOURCES AND USES OF CASH

Our liquidity for the three months ended March 31, 2022 was primarily derived from net cash provided by operating activities and cash on hand. During the three months ended March 31, 2022, we also received supplemental funds from federal grants provided under COVID‑19 relief legislation. We had $1.405 billion of cash and cash equivalents on hand at March 31, 2022 to fund our operations and capital expenditures, and our borrowing availability under our credit facility was $1.500 billion based on our borrowing base calculation at March 31, 2022.

When operating under normal conditions, our primary source of operating cash is the collection of accounts receivable. As such, our operating cash flow is impacted by levels of cash collections, as well as levels of implicit price concessions, due to shifts in payer mix and other factors. Our Credit Agreement provides additional liquidity to manage fluctuations in operating cash caused by these factors.

Net cash provided by operating activities was $228 million in the three months ended March 31, 2022 compared to $534 million in the three months ended March 31, 2021. Key factors contributing to the change between the 2022 and 2021 periods include the following:

- $194 million of Medicare advances recouped in the three months ended March 31, 2022 compared to no amounts recouped during the same period in 2021;
- $5 million of cash received from grants in the three months ended March 31, 2022 compared to $31 million received in the three months ended March 31, 2021;
- Decreased cash receipts of $12 million related to supplemental Medicaid programs in California and Texas; and
- The timing of other working capital items.

We used net cash of $60 million and $145 million in investing activities during the three months ended March 31, 2022 and 2021, respectively. The decrease in cash used of $85 million between the 2022 and 2021 periods was attributable to an increase of $135 million in proceeds from the sale of facilities and other assets, primarily related to the sale of several medical office buildings in 2022. This was partially offset by higher capital expenditures of $34 million and an increase of $15 million in cash used for purchases of businesses or joint venture interests in the three months ended March 31, 2022 compared to the same period in 2021.

Net cash used in financing activities was $1.127 billion for the three months ended March 31, 2022 compared to $694 million for the three months ended March 31, 2021. Financing activity in the 2022 period included payments of $879 million to reduce our long-term debt, including $730 million paid to redeem all $700 million aggregate principal amount outstanding of our 2025 Senior Secured First Lien Notes and $107 million paid to repurchase $103 million aggregate principal amount outstanding of our 2023 Senior Unsecured Notes. In addition, we paid total distributions to noncontrolling interest holders of $135 million, funds held for USPI’s unconsolidated affiliates for which we provide cash management services decreased by $80 million and we made payments of $27 million related to our stock‑based compensation plans. Net cash used in financing activities during the three months ended March 31, 2021 included payments of $541 million to reduce our long-term debt, including a payment of $495 million to retire our 7.000% senior unsecured notes due 2025, and distributions to noncontrolling interest holders of $119 million.

We record our equity securities and our debt securities classified as available‑for‑sale at fair market value. The majority of our investments are valued based on quoted market prices or other observable inputs. We have no investments that we expect will be negatively affected by the current economic conditions such that they will materially impact our financial condition, results of operations or cash flows.

### DEBT INSTRUMENTS, GUARANTEES AND RELATED COVENANTS

*Credit Agreement—*At March 31, 2022, our Credit Agreement provided for revolving loans in an aggregate principal amount of up to $1.500 billion with a $200 million subfacility for standby letters of credit. In March 2022, we amended the revolving credit facility to, among other things, (i) decrease the previous maximum aggregate revolving credit commitments from $1.900 billion to $1.500 billion, subject to borrowing availability, (ii) extend the scheduled maturity date from September 2024 to March 2027, and (iii) replace the London Interbank Offered Rate (LIBOR) with the Term Secured Overnight Financing Rate (“SOFR”) and Daily Simple SOFR (each, as defined in the Credit Agreement) as the reference interest rate. At March 31, 2022, we had no cash borrowings outstanding under the Credit Agreement, and we had less than $1 million of standby letters of credit outstanding. Based on our eligible receivables, $1.500 billion was available for borrowing under the Credit Agreement at March 31, 2022. At March 31, 2022, we were in compliance with all covenants and conditions in our Credit Agreement.

*Letter of Credit Facility—*We have a letter of credit facility (as amended to date, the “LC Facility”) that provides for the issuance, from time to time, of standby and documentary letters of credit in an aggregate principal amount of up to $200 million. The scheduled maturity date of the LC Facility is September 12, 2024. The LC Facility is subject to an effective maximum secured debt covenant of 4.25 to 1.00. At March 31, 2022, we were in compliance with all covenants and conditions in the LC Facility, and we had $138 million of standby letters of credit outstanding thereunder.

*Senior Unsecured Notes and Senior Secured Notes—*On February 23, 2022, we redeemed all $700 million aggregate principal amount outstanding of our 2025 Senior Secured First Lien Notes in advance of their maturity date. We paid $730 million from cash on hand to redeem the notes. In connection with the redemption, we recorded a loss from early extinguishment of debt of $38 million in the three months ended March 31, 2022, primarily related to the difference between the purchase price and the par value of the notes, as well as the write‑off of associated unamortized issuance costs.

In addition, in March 2022, we repurchased $103 million aggregate principal amount outstanding of our 2023 Senior Unsecured Notes through a series of open‑market transactions. We paid $107 million from cash on hand to complete these transactions. In connection with the repurchases, we recorded a loss from early extinguishment of debt of $5 million in the three months ended March 31, 2022, primarily related to the difference between the purchase prices and the par value of the notes, as well as the write‑off of associated unamortized issuance costs.

For additional information regarding our long-term debt, see Note 6 to the accompanying Condensed Consolidated Financial Statements and Note 8 to the Consolidated Financial Statements included in our Annual Report.

### LIQUIDITY

We continue to experience negative impacts of the COVID‑19 pandemic on our business in varying degrees. During January and February 2022, we were affected by a significant acceleration in COVID‑19 cases associated with the Omicron variant. Future variants could similarly emerge and cause surges in COVID‑19 cases, which may adversely impact the local economies of areas we serve. Any increase in the amount of or deterioration in the collectability of patient accounts receivable could adversely affect our cash flows and results of operations. If general economic conditions deteriorate or remain uncertain for an extended period of time, our liquidity and ability to repay our outstanding debt may be impacted.

We have taken, and continue to take, various actions to increase our liquidity and mitigate the impact of reductions in our patient volumes and changes in our service mix and revenue mix. These actions included the sale and redemption of various senior unsecured notes and senior secured notes, which eliminated any significant debt maturities until June 2023 and will reduce our future annual cash interest expense payments. In addition, we have continued cost-efficiency measures, as well as necessary cost reductions, to substantially offset incremental costs, including temporary staffing and premium pay, as well as higher supply costs for PPE. We have also sought to compensate for the COVID‑19 pandemic’s disruption of our patient volumes and service mix by growing our services for which demand has been more resilient, including our higher‑acuity service lines. While the length of time that will be required for our patient volumes and mix to return to pre-pandemic levels is unknown, especially demand for lower‑acuity services, we believe demand for our higher‑acuity service lines will continue to grow. We believe these actions, together with government relief packages, supported our ability to provide essential patient services during the initial uncertainty caused by the COVID‑19 pandemic and continue to do so.

From time to time, we expect to engage in additional capital markets, bank credit and other financing activities depending on our needs and financing alternatives available at that time. We believe our existing debt agreements provide flexibility for future secured or unsecured borrowings.

Our cash on hand fluctuates day‑to‑day throughout the year based on the timing and levels of routine cash receipts and disbursements, including our book overdrafts, and required cash disbursements, such as interest payments and income tax payments, as well as cash disbursements required to respond to the COVID‑19 pandemic. Cash flows from operating activities in the first quarter of the calendar year are usually lower than in subsequent quarters of the year, primarily due to the timing of certain working capital requirements during the first quarter, including our annual 401(k) matching contributions and annual incentive compensation payouts. These fluctuations result in material intra-quarter net operating and investing uses of cash that have caused, and in the future may cause, us to use our Credit Agreement as a source of liquidity. We believe that existing cash and cash equivalents on hand, borrowing availability under our Credit Agreement and anticipated future cash provided by our operating activities should be adequate to meet our current cash needs. These sources of liquidity, in combination with any potential future debt incurrence, should also be adequate to finance planned capital expenditures, payments on the current portion of our long-term debt, payments to joint venture partners, including those related to put and call arrangements, and other presently known operating needs.

Long-term liquidity for debt service and other purposes will be dependent on the amount of cash provided by operating activities and, subject to favorable market and other conditions, the successful completion of future borrowings and potential refinancings. However, our cash requirements could be materially affected by the use of cash in acquisitions of businesses, repurchases of securities, the exercise of put rights or other exit options by our joint venture partners, and contractual commitments to fund capital expenditures in, or intercompany borrowings to, businesses we own. In addition, liquidity could be adversely affected by a deterioration in our results of operations, including our ability to generate sufficient cash from operations, as well as by the various risks and uncertainties discussed in this section, other sections of this report and in our Annual Report, including any costs associated with legal proceedings and government investigations.

We do not rely on commercial paper or other short-term financing arrangements nor do we enter into repurchase agreements or other short-term financing arrangements not otherwise reported in our balance sheet. In addition, we do not have significant exposure to floating interest rates given that all of our current long-term indebtedness has fixed rates of interest except for borrowings under our Credit Agreement.

### CRITICAL ACCOUNTING ESTIMATES

In preparing our Condensed Consolidated Financial Statements in conformity with GAAP, we must use estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable, given the particular circumstances in which we operate. Actual results may vary from those estimates.

We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different outcomes under different conditions or when using different assumptions.

Our critical accounting estimates have not changed from the description provided in our Annual Report.

## Market risk

As filed, 1,317 characters.

The following table presents information about certain of our market-sensitive financial instruments at March 31, 2022. The fair values were determined based on quoted market prices for the same or similar instruments. The average effective interest rates presented are based on the rate in effect at the end of the reporting period. The effects of unamortized discounts and issue costs are excluded from the table.

*(Dollars in Millions)*

|  | Maturity Date, Years Ending December 31, 2022 | 2023 | 2024 | 2025 | 2026 | Thereafter | Total | Fair Value |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Fixed rate long-term debt | $102 | $1,894 | $1,455 | $46 | $2,120 | $9,371 | $14,988 | $14,876 |
| Average effective interest rates | 4.1% | 6.6% | 4.6% | 5.7% | 4.9% | 5.4% | 5.4% |  |

We have no affiliation with partnerships, trusts or other entities (sometimes referred to as “special-purpose” or “variable-interest” entities) whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements by us. As a result, we have no exposure to the financing, liquidity, market or credit risks associated with such entities. We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage or prepayment features.

## Controls and procedures

As filed, 1,081 characters.

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined by Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this report. The evaluation was performed under the supervision and with the participation of management, including our chief executive officer and chief financial officer. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective as of March 31, 2022 to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the Exchange Act and the SEC rules thereunder.

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 2,049 characters.

This section supplements and updates certain of the information found under Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021 (the “Annual Report”) based on information currently known to us and recent developments since the filing of the Annual Report.

***A cybersecurity incident we recently experienced could result in negative impacts on our business.***

In April 2022, we experienced a cybersecurity incident that temporarily disrupted a subset of our acute care operations and involved the exfiltration of certain confidential company and patient information. During this time, our hospitals remained operational and continued to deliver patient care safely and effectively, utilizing well‑established back‑up processes. We immediately suspended user access to impacted information technology applications, executed extensive cybersecurity protection protocols, and took steps to restrict further unauthorized activity. Promptly after the incident, we began to restore impacted information technology operations and launched an investigation of the incident, which investigation is ongoing, to determine, among other things, the full extent of the company and patient information involved. We are also continuing the process of fully restoring impacted information technology operations. As with any cybersecurity incident, system interruption or unavailability of our information systems or of third-party systems with access to our data, this cybersecurity incident could result in: the unauthorized disclosure, misuse, loss or corruption of such data; interruptions and delays in our normal business operations (including the collection of revenues); patient harm; potential liability under privacy, security, consumer protection or other applicable laws; significant recovery costs or regulatory penalties; and negative publicity and damage to our reputation. Any of these could have a material adverse effect on our business, financial condition, results of operations or cash flows.

Filed Apr 29, 2022.
Source: SEC EDGAR, the filing index for accession 0000070318-22-000029. Last ingested by Listed: Nov 15, 2026, 02:42 ET. No prices; not investment advice.
